MedTrace Logo

The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD

NCT00741767 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-10-06

No results posted yet for this study

Summary

The purpose of this study is to determine if Advair Diskus improves sleep quality by reducing lung hyperinflation in COPD.

Conditions

Interventions

DRUG

salmeterol-fluticasone

250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily

Sponsors & Collaborators

Principal Investigators

  • Ravi Kalhan, MD, MS · Northwestern University

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2010-09-30
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00741767 on ClinicalTrials.gov